Chinese Embassy Spokesperson's Remarks on the FDA's Approval of TCM Lianhua Qingwen Capsule
The Chinese Embassy in the Philippines is glad to learn that the Philippine Food and Drug Administration (FDA) has approved Chinese drug Lian Hua Qing Wen produced by one of China's renowned Traditional Chinese Medicine (TCM) manufacturers, Shijiazhuang Yiling Pharmaceutical Co. Ltd., making the drug formally registered as TCM in the Philippines. This marks an important progress in the entry of TCM products into the Philippine market, which we welcome.
Lianhua Qingwen Capsule is an approved COVID-19 treatment for mild and moderate cases in China. So far, Lianhua Qingwen Capsule has been approved in Hong Kong and Macao SAR of China, Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos PDR. It is our sincere hope that its entrance into the Philippine market will contribute to the fight against the spread of COVID-19 in this country and help the patients with mild and moderate symptoms recover.
The Embassy advises the consumers to purchase and consume authentic TCM produced by qualified pharmaceutical manufacturers, and hopes that TCM would play a bigger role to support the efforts of the Philippine government and its people to fight against COVID-19 until the final victory.